Pharmaceutical regulatory environment: Challenges and opportunities in the gulf region

Pharmaceutical Regulatory Environment: Challenges and Opportunities in the Gulf Region

Volumn , Issue , 2015, Pages 1-236

  Al Essa, Reem K ^a   Al Rubaie, Mohammed ^b   Walker, Stuart ^c   Salek, Sam ^d  

^a Kuwait Advancement for Conference and Exhibition Management Est Kuwait City   (Kuwait)

^b Centre for Innovation in Regulatory Science ^*  (Oman)

^c Centre for Innovation in Regulatory Science   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944059591     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-17590-4     Document Type: Book

References (174)

1. Abraham, J. (2002). The pharmaceutical industry as a political player. Medicines, society, and industry II. The Lancet, 360, 1498-1502.
2. Alder, S. (2001). Methods for setting parameters for submission quality: How do we Know id we have got them right? In C. Hynes, N. McAuslane, & S. Walker (Eds.), Building quality measures into the regulatory review process: Assessing the needs of industry and regulators (pp. 39-42). Surrey: CMR International.
3. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. The Welsh School of Pharmacy, Cardiff University. Doctor of Philosophy thesis.
4. ALPEN Capital Investment Banking. (2013). GCC Pharmaceuticals Industry. [Online]. Available from: http://www.alpencapital.com/downloads/GCC%20Pharmaceuticals%20Industry%20Report%202013_31%20March%202013.pdf
5. Anderson, C. (2004). An evaluation of harmonisation in the regulatory environment and its impact on patients’ access to new medicines. Unpublished Doctor of Philosophy, Welsh School of Pharmacy. Cardiff University.
6. Anderson, C., McAuslane, N., & Walker, S. (2002). The impact of the changing regulatory environment on review times (R&D Briefing 35). [Online] Surrey: CMR International. Available from: http://www.cmr.org/institute
7. Booz Allen Hamilton Inc. (2006). Independent evaluation of FDA’s first cycle review performanceretrospective analysis final report. Available at: http://www.fda.gov/ope/pdufa/PDUFA1stCycle/default.htm
8. Booz Allen Hamilton Inc. (2008). Independent evaluation of FDA’s first cycle review performance - Final report. Available from: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm127117.htm
9. Bujar, M., & McAuslane, N. (2014). The impact of the changing regulatory environment on the approval of new medicines across six major authorities 2004-2013 (R&D Briefing 55).
10. Centre for Innovation in Regulatory Science (CISR). Available at: http://www.fdanews.com/ext/resources/files/01-15/01-14-2015-International-Drug-Approvals.pdf?1421272458
11. CIA World Factbook. Available at: https://www.cia.gov/library/publications/the-world-factbook.(Accessed in 2013 and 2014).
12. CMR International Institute for Regulatory Science. (1997). Mapping the milestones: Similarities and differences in review processes (R&D Briefing № 11). [Online] Surrey: CMR International. Available from: http://www.cmr.org/institute
13. CMR International Institute for Regulatory Science. (2001). Asia update: Key issues in the registration of pharmaceuticals (R&D Briefing № 32B). [Online] Surrey: CMR International. Available from: http://cmr.thomsonreuters.com/pdf/32b.pdf
14. Cocchetto, D. (2000). The food and drug administration’s fast track designation. Drug Information Journal, 34, 753-760.
15. Cone, M., & McAuslane, N. (2006). Building quality into regulatory activities: What does it mean? (R&D Briefing 46). [Online] Surrey: CMR International. Available from: http://www.cmr.org/institute
16. Coplan, P. M., Noel, R. A., Levitan, B. S., Ferguson, J., & Mussen, F. (2011). Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clinical Pharmacology & Therapeutics, 89 (2), 312-315.
17. Dureja, H. (2010). New drug approval process: Regulatory view. Pharmainfo.net, 8 (4). Available at: http://www.pharmainfo.net/reviews/new-drug-approval-proces
18. European Medicines Agency (EMA). (2009). Survey 2008 on the performance of EMEA scientific procedures for medicinal products for human use (EMEA/MB/30754/2009). London: EMA. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500006220.pdf
19. European Medicines Agency (EMA). (2012). Benefit-risk methodology project work package 4 report: Benefit-risk tools and process. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/03/WC500123819.pdf
20. Foo, Y. T. (2006). Submission management: Singapore’s model. 7th Middle East Regulatory conference, Dubai, 14th-16th November 2006. Drug Information Journal, 41, 415-416.
21. Greg Nixon, Y., & Trombe, E. (2013). The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy, The Welsh School of Pharmacy, Cardiff University.
22. Hill, S., & Johnson, K. (2004). Emerging challenges and opportunities in drug registration and regulation in developing countries. London: DFID Health Systems Resources Centre.
23. Hirako, M., McAuslane, N., Salek, S., Anderson, C., & Walker, S. (2007). A comparison of the drug review process at five international regulatory agencies. Drug Information Journal, 41, 291-308.
24. Horner, A. (2005). Comparison of a global submission of new biological entity and a new chemical entity - Strategic decisions and criteria for implementation. Doctor of Philosophy, Mathematisch-Naturwissenschaftlichen Fakultät, Rheinischen Friedrich-Wilhelms-Universität Bonn.
25. Hynes, C., McAuslane, N., & Walker, S. (Eds.). (2001). Building quality measures into the regulatory review process: Assessing the needs of industry and regulators. Surrey: CMR International Institute for Regulatory Science.
26. International Conference on Harmonisation (ICH). (2011). Global Cooperation Group. [Online] Available from: http://www.ich.org/about/organisation-of-ich/coopgroup.html
27. Jefferys, D. (1997). How do you measure the quality of the scientific assessment and the review process? The view of the MCA. In N. McAuslane & S. R. Walker (Eds.), Improving the regulatory review process: Assessing performance and setting targets (pp. 115-123). Kluwer Academic Publishers. Center for Medicines Research (CMR), UK.
28. Karlton, P. C., & Johnson, D. (1997). An integrated approach to the preparation of global CMC dossiers. Drug Information Journal, 31, 237-242.
29. Korteweg, M. (2003). Benchmarking quality management systems of regulatory authorities to ensure harmonised good regulatory practices for medicinal products. London: Chartered Quality Institute (CQI). Available from: http://www.thecqi.org/
30. Lilja, J., Salek, S., Alvarez, A., & Hamilton, D. (2008). Pharmaceutical systems: Global perspectives. Chichester: Wiley. Hardcover. Available at: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0470725672.html
31. Lumpkin, M. (2000). Assessing quality of the regulatory review function. Drug Information Association, Annual meeting, San Diego.
32. Mallia-Milanes, A. (2010). The development and application of scorecards to assess the quality of regulatory submissions and their review. Unpublished Doctor of Philosophy, Welsh School of Pharmacy. Cardiff, Cardiff University.
33. McAuslane, N., Anderson, C., & Walker, S. (2004) The changing regulatory environment: reality and perception? (R&D Briefing № 42). Surry: CMR International. Available at: http://www.cmr.org/institute
34. McAuslane, N., Cone, M., Collins, J., & Walker, S. (2006). Building quality into regulatory activities: What does it mean? (R&D Briefing № 46). [Online] Surrey: CMR International Institute for Regulatory Science. Available from: http://www.cmr.org/institute
35. McAuslane, N., Cone, M., Collins, J., & Walker, S. (2009). Emerging markets and emerging agencies: A comparative study of how key regulatory agencies in Asia, Latin America, the Middle East and Africa are developing processes and review models for new medicinal products. Drug Information Journal, 43, 349-359.
36. Molzon, J. A. (2010). The value and benefits of ICH to drug regulatory authorities - advancing harmonization for better health. ICH 20th anniversary publication. Available at: http://www.ich.org/home.html
37. Molzon, J. A., Giaquinto, A., Lindstorm, L., Tominaga, T., Ward, M., & Doerr, P. (2011). The value and benefits of the International conference on harmonization to Drug Regulatory Authorities: Advancing Harmonization for better Public Health. Clinical Pharmacology and Therapeutics, 89 (4), 503-512.
38. Morgan, S. G., McMahon, M., Mitton, C., Roughead, E., Kirk, R., & Kanavos, P. (2006). Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff (Millwood), 25 (2), 337-347.
39. Moss, F. (2004). Transforming health: From policy to action (pp. 29-30). University of Cambridge, Judge Institute of Management, Cambridge’s Business School.
40. Mourshed, MH., Hedigar, V., & Lambert, VT. (2007). Gulf Cooperation Council Healthcare: Challenges and opportunities. Arab World Competitiveness Report Part 5 (pp. 55-64). Dubai: Mckinsey and Company. Available at: http://www.weforum.org/pdf/Global_Competitiveness_Reports/Reports/chapters/2_1.pdf
41. Patel, P. (2014). Graph obtained from Center of Innovation for Regulatory Science (CIRS). Emerging Market Report.
42. Rawson, N. S. B. (2000). Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998. Canadian Medical Association Journal, 4 (162), 501-504.
43. Ratanwijitrasin S, Wondemagegnehu E. (2002). Effective drug regulation. A multicountry study. Geneva: World Health Organization. Available at: http://apps.who.int/medicinedocs/pdf/s2300e/s2300e.pdf
44. Torstensson, D., & Pugatch, M. (2010). Keeping medicines safe: A study of the regulations guiding the approval of medicines in emerging markets. Available from: http://www.stockholmnetwork.org
45. Trouiller, P., Salmen, R., Myhr, K., Folb, P., Weerasuriya, K., & Gray, A. (2002) The globalization of regulatory requirements, and the development and availability of medicinal products in developing countries: quality, efficacy and safety issues. MSF/DND/Working Group: The Crisis of Neglected Diseases, Developing Treatments and Ensuring Access, New York. Tufts Center for the Study of Drug Development. Costs to develop and win marketing approval for a new drug is $2.6 billion News release, November 18, 2014. Available at: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study. Accessed December 17, 2014.
46. United States Pharmacopeia (USP) Drug Quality Information Program. (2007). Ensuring the quality of medicines in resource-limited countries: An operational guide. Rockville: The United States Pharmacopeial Convention. Available from: http://www.usp.org/worldwide/dqi/resources/technicalReports
47. Vernengo, M. J., de Joncheere, K., & Fefer, E. (1998). Advances in pharmaceutical market integration in MERCOSUR and other Latin American countries. Drug Information Journal, 32 (3), 831-839.
48. Walker, S., & Cone, M. (2004). Benefit-risk assessment: Summary report on the Workshop on the development of a model for benefit-risk assessment of medicines based on multi-criteria decision analysis. Surrey: CMR International.
49. Walker, S., Cone, M., McAuslane, N., & Collins, J. (2007). Emerging markets models of best practice for the regulatory review of new medicines. Report of the CMR International Institute workshop. Surrey: CMR International.
50. Wikipedia, the Free Encyclopedia. Cooperation Council for the Arab States of the Gulf. Available from: http://en.wikipedia.org/wiki/Cooperation_Council_for_the_Arab_States_of_the_Gulf. Accessed 1 June 2014.
51. World Health Organisation (WHO). (2002). The impact of implementation of ICH guidelines in Non-ICH Countries. [Online] Geneva: WHO. Available from: http://apps.who.int/medicinedocs/pdf/h2993e/h2993e.pdf
52. World Health Organisation (WHO). (2003a). Annual report 2002, essential drugs and medicines policy: Supporting countries to close the access gap. 9. WHO, 1211 Geneva 27.
53. World Health Organisation (WHO). (2003b). WHO policy perspectives on medicines: Effective medicines regulation: ensuring safety, efficacy and quality. [Online] Geneva: WHO. Available from: http://www.who.int/medicinedocs/pdf/s4921e/s4921e.pdf
54. World Health Organisation (WHO). (2004). WHO Medicines Strategy Countries at the core 2004-2007. 2. WHO, 1211 Geneva 27.
55. World Health Organisation (WHO). (2008). WHO Drug Information, 22 (2). Available from: http://apps.who.int/medicinedocs/index/assoc/s14886e/s14886e.pdf
56. World Health Organization. (2010). Regulatory harmonization. Updating medicines regulatory systems in Sub-Saharan African countries. WHO Drug Information, 24 (1): 620.
57. Zellerhoff, K. (2001). How the quality of the dossier affects the quality of the review: A company’s perspective. In C. Hynes, N. McAuslane, & S. Walker (Eds.), Building quality measures into the regulatory review process: Assessing the needs of industry and regulators (pp. 33-37). Surrey: CMR International Institute for Regulatory Science.
58. Bahrain Ministry of Health (2008). Bahrain Medicine Policy (BMP): Aims, Present Situation and Policy Objectives, BMP Task Force Draft version 7.
59. Caroll, J. (2012). The accelerated approval debate: Faster FDA drug approvals may mean less efficacy data. The Federal Line. Biotechnology Healthcare, 9 (2), 6-7.
60. Crout, J. R. (1998). Fifty years of drug regulation: Solid accomplishments and an important future. WHO Drug Information, 12 (1), 3-5.
61. Deng, R., & Kaitin, K. (2004). The regulation and approval of new drugs in China. Drug Information Journal, 37, 29-39.
62. Dimmitt, C., Carey, J., & Hatch, T. (2007). Evidence-based school counselling: Making a difference with data-driven practices. Thousand Oaks: Corwin.
63. European Medicines Agency (EMA). (2009). Survey 2008 on the performance of EMEA scientific procedures for medicinal products for human use (EMEA/MB/30754/2009). London: EMA. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500006220.pdf
64. Foo, Y. T. (2006). Submission Management: Singapore’s Model. In: 7th Middle East Regulatory Conference. Dubai, 14th-16th November 2006. Drug Information Journal 41, 415-416.
65. Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy, The Welsh School of Pharmacy, Cardiff University.
66. Health Canada (HC) (2006). Access to Therapeutic Products: The Regulatory Process in Canada. [Online] Canada: HC. Available from: http://www.hc-sc.gc.ca/ahc-asc/pubs/hpfb-dgpsa/access-therapeutic_acces-therapeutique-eng.php.
67. Health Science Authority (HSA) (2010). Health Science Authority Annual Report. [Online] Singapore: HSA. Available from: http://www.hsa.gov.sg.
68. Hirako, M., McAuslane, N., Salek, S., Anderson, C., & Walker, S. (2007). A comparison of the drug review process at five international regulatory agencies. Drug Information Journal, 41, 291-308.
69. Lu, D., & Huang, W. (2010). Overview of drug evaluation system in China. Scientific Research Essays, 5 (6), 514-518.
70. McAuslane, N., Cone, M., Collins, J. & Walker, S. (2009). Emerging Markets and Emerging Agencies: A Comparative Study of How Key Regulatory Agencies in Asia, Latin America, the Middle East and Africa are developing processes and review models for new medicinal products. Drug Information Journa, 43, 349-359
71. McAuslane, N., Anderson, C., & Walker, S. (2004). The changing regulatory environment: Reality and perception? R&D Briefing № 42. [Online] Surrey: CMR International. Available from: http://www.cmr.org/institute
72. Medecins San Frontiers (MSF). (2005). Will the lifeline of affordable medicines for poor countries be cut? Consequences if medicines patenting in India. Medecins Sans Frontieres Campaign for Access to Essential Medicines. Briefing Document. [Online] Geneva: MSF. Available from: www.accessmed-msf.org
73. Neumann, P. J., & Johanneson, M. (1994). From principle to public policy: Using cost-effectiveness analysis. Health Affairs, 13 (3), 206-214.
74. Ratanawijitrasin, S., & Wondemagegnehu, E. (2002). Effective drug regulation - A multicountry study. [Online] Geneva: WHO. Available from: http://pdfoo.com/ebook-4146/effective-drugregulation.html
75. Rehnquist, J. (2003). FDA’s review process for new drug applications: A management review. Department of Health and Human Services (DHHS), Office of Inspector General. Available from: http://oig.hhs.gov/oei/reports/oei-01-01-00590.pdf
76. Thaul, S. (2008). FDA fast track and priority review programs. CRS Report for Congress. Order Code RS22814. [Online]. Available from: http://www.nationalaglawcenter.org/assets/crs/RS22814.pdf
77. Therapeutic Goods Administration (TGA). (2009). Guidance for industry on providing regulatory submissions for prescription medicines in electronic format (eCTD) in Australia. Available from: http://www.theectdsummit.com/?m=200901
78. Tufts Centre for the Study of Drug Development. (2014, November 18). Costs to develop and win marketing approval for a new drug is $2.6 billion. News release. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study. Accessed 17 Dec 2014
79. United States Food and Drug Administration. (2010). FDA-Industry PDUFA V reauthorisation meeting. Silver Spring: FDA White Oak Campus. Available from: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM241075.pdf
80. United States Food and Drug Administration (US FDA) (2012). Guidance for Industry and Food and Drug Administration Staff - FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals. Available from: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm089733.htm
81. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University.
82. Barrocliffes, S. (1994). Developing a global regulatory strategy. Drug Information Journal, 28, 525-531.
83. Canadian drug review process. (2006). Available from: http://www.hc-sc.gc.ca/hpb-dgps/therapeut
84. Donnelly, E., Ritchie, J., & French, S. (1996). Company strategies to ensure a quick and efficient review: A transnational company. In C. E. Lunlay & S. R. Walker (Eds.), Improving the regulatory review process: Industry and regulatory initiatives (pp. 41-52). Lancaster: Kluwer Academic Publishers.
85. Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University.
86. Hirako, M., McAuslane, N., Salek, S., Anderson, C., & Walker, S. (2007). A comparison of the drug review process at five international regulatory agencies. Drug Information Journal, 41, 291-308.
87. Lumley, C. E, & Walker, S. R. (Eds.). (1996). Improving the regulatory review process, CMR workshop series. Industry and regulatory initiatives (pp. 1-20). Lancaster: Kluwer Academic Publishers.
88. Rawson, N. S. B. (2000). Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998. Canadian Medical Association Journal, 4 (162), 501-504.
89. Rehnquist, J. (2003). FDA’s review process for new drug applications: A management review. Department of Health and Human Services (DHHS), Office of Inspector General. Available at: http://oig.hhs.gov/oei/reports/oei-01-01-00590.pdf
90. Abdul, H., & Ali, M. (1997). Training and professional development. In B. E. Swanson, P. B. Bentz & A. J. Sofranko (Eds.), Improving agricultural extension: A reference manual. [Online] Rome: Food and Agricultural Organisation (FAO) of the United Nations. ISBN: 92-5-1040029. Available from: http://fao.org/docrep/w5830e/w5830e0h.htm
91. Brown, L. D., Franco, L. M., Rafeh, N., & Halzel, T. (1998). Quality assurance of health care in developing countries (Quality assurance methodology refinement series). Bethesda: Quality Assurance Project. Available from: http://www.hrhresourcecenter.org/node/796
92. CMR International Institute for Regulatory Science. (1997). Mapping the milestones: Similarities and differences in review processes. R&D Briefing № 11 [Online]. Surrey: CMR International. Available from: http://www.cmr.org/institute
93. Compass West Consulting, LLC. (2008). Importance of feedback [Online]. Arizona: Compass West Consulting. Available from: http://compasswestllc.com
94. Cone, M., & McAuslane, N. (2006). Building quality into regulatory activities: What does it mean? R&D Briefing 46 [Online]. Surrey: CMR International. Available from: http://www.cmr.org/institute
95. Deng, R., & Kaitin, K. (2004). The regulation and approval of new drugs in China. Drug Information Journal, 37, 29-39.
96. Donabedian, A. (2005). Evaluating the quality of medical care. Milbank Quarterly, 83 (4), 691-729.
97. Garrett, M. (2009). Good review practices at the US FDA. Regulatory Rapporteur, 6 (12), 22-23.
98. Health Canada (HC). (2006). Access to therapeutic products: The regulatory process in Canada [Online]. Canada: HC. Available from: http://www.hc-sc.gc.ca/ahc-asc/pubs/hpfb-dgpsa/access-therapeutic_acces-therapeutique-eng.php
99. Health Canada (HC). (2008). Therapeutic products directorate, good review practice project [Online]. Canada: HC. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/practice-pratique/grp_fs_bpe_fd_v2-eng.php
100. Health Science Authority (HSA). (2010). Health science authority annual report [Online]. Singapore: HSA. Available from: http://www.hsa.gov.sg
101. Mallia-Milanes, A. (2006). An evaluation of quality measures applied to the regulatory review process of major regulatory authorities. Unpublished Master of Philosophy Thesis, The Welsh School of Pharmacy, University of Wales.
102. Mallia-Milanes, A. (2010). The development and application of scorecards to assess the quality of regulatory submissions and their review. Unpublished Doctor of Philosophy thesis, Welsh School of Pharmacy, Cardiff University, Cardiff.
103. Moran, M., Guzman, J., McDonald, A., Wu, L., & Omune, B. (2010). Registering new drugs: The African context-new tools for new times [Online]. Sydney: The George Institute for International Health. Available from: http://www.policycures.org/downloads/DNDi_Registering_New_Drugs-The_African_Context_20100108.pdf
104. Morgan, S. G., McMahon, M., Mitton, C., Roughead, E., Kirk, R., Kanavos, P., & Menon, D. (2006). Centralized drug review processes in Australia, Canada, New Zealand, and the UK. Health Affairs, 25 (2), 337-347.
105. Muir, R. (2007, July). Decision-making by committee: Perceptions and misperceptions [Online]. Available from: http://articles.practice.findlaw.com/2007/Jul/30/301.html
106. Pantang, G. (2003). The importance of communication. Hong Kong Medical Journal, 9 (5), 389-390.
107. Torstensson, D., & Pugatch, M. (2010). Keeping medicines safe: A study of the regulations guiding the approval of medicines in emerging markets. Available from: http://www.stockholmnetwork.org
108. United States Food and Drug Administration. (2009). Manual of policies and procedures (CDER). FDA. Available from: http://www.fda.fov/aboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/default.hm
109. World Health Organisation (WHO). (2001). How to develop and implement a national drug policy (2nd ed.). Updates and replaces: Guidelines for developing national drug policies (1988). Available from: http://www.who.int/medicinedocs/pdf/s2283e.pdf
110. American Pharmaceutical Group (APG). (2010). Ensuring access to essential medicines in developing countries. [Online] London: APG. Available from: www.apg.uk.com
111. CMR International Institute for Regulatory Science. (2009). Review and reimbursement: A special case for better cooperation. CMR International Institute for Regulatory Science Workshop, Surrey, 29-30 September. Surrey: CMR International. Available from: http://www.cmr.org/institute
112. Eichler, H., Pignatti, F., Bruno, F., Leufkens, H., & Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma. Nature Reviews Drug Discovery, 7, 818-826.
113. Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy, The Welsh School of Pharmacy, Cardiff University.
114. Matsebula, T., Goudge, J., & Gilson, L. (2005). Regulating the pharmaceutical sector: Coping with low capacity while maintaining regulatory independence. Health Economics Financing Programme (HEFP) Working Paper 01/05. [Online] South Africa: Centre for Health Policy, University of Witwatersrand. Available from: http://www.hefp.lshtm.ac.uk/publications/downloads/working_papers/01_05.pdf
115. Al-Essa, R. (2014, May 12-14). Kuwait conference and exhibition on National Pharmacovigilance Strategies. Ministry of Health of Kuwait and the Executive Board of Health Ministers’ Council for GCC States. Crowne Plaza Hotel, State of Kuwait.
116. Alessa, R., Salek, S., & Walker, S. (2011). The development of a strategic plan for strengthening the drug regulation in the Gulf region. Script Regulatory Affairs. Informa UK Ltd. http://cirsci.org/sites/default/files/SRA_Sept_Al-Essa_Salek_Walker_The%20development%5B1%5D.pdf.
117. Bahri, P., & Harrison-Woolrych, M. (2012). Focusing on risk communication about medicines: Why now? Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 35 (11), 971-975.
118. Bouder, F. (2011). Benefit/risk communication by the European Medicines Agency: A study of influential stakeholders’ expectations and attitudes. Maastricht: Department of Technology and Society Studies, Maastricht University.
119. Chused, A. E., Kuperman, G. J., & Stetson, P. D. (2008). Alert override reasons: A failure to communicate. AMIA Annual Symposium Proceedings/AMIA Symposium AMIA Symposium, 111-5.
120. Corry, M., Bonner, G., McEntee, S., Dugan, J., & MacAuley, D. (2000). Hospitals do not inform GPs about medication that should be monitored. Family Practice, 17 (3), 268-271.
121. Cullen, G., Kelly, E., & Murray, F. E. (2006). Patients’ knowledge of adverse reactions to current medications. British Journal of Clinical Pharmacology, 62 (2), 232-236.
122. Division ESaC. (2013). The patient’s voice in the evaluation of medicines. How patients can contribute to assessment of benefit and risk. EMA/607864/2013. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/10/WC500153276.pdf.
123. Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., Conti, R., Huskamp, H. A., Zhu, S., et al. (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care, 50 (6), 466-478.
124. Giofre, C., Scicchitano, F., Palleria, C., Mazzitello, C., Ciriaco, M., Gallelli, L., et al. (2013). Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. Journal of Pharmacology & Pharmacotherapeutics, 4 (Suppl 1), S55-S60.
125. Mammi, M., Citraro, R., Torcasio, G., Cusato, G., Palleria, C., & di Paola, E. D. (2013). Pharmacovigilance in pharmaceutical companies: An overview. Journal of Pharmacology & Pharmacotherapeutics, 4 (Suppl 1), S33-S37.
126. Mazzitello, C., Esposito, S., De Francesco, A. E., Capuano, A., Russo, E., & De Sarro, G. (2013). Pharmacovigilance in Italy: An overview. Journal of Pharmacology & Pharmacotherapeutics, 4 (Suppl 1), S20-S28.
127. McAuslane, N., & Walker, S. (2013). The patient’s voice in clinical development: Can patients contribute to the benefit-risk assessment of new medicines? Centre for Innovation in Regulatory Science. http://cirsci.org/sites/default/files/CIRS_March_2013_Workshop_290514_lowres.pdf.
128. Mehta, U., Dheda, M., Steel, G., Blockman, M., Ntilivamunda, A., Maartens, G., Pillay, Y., & Cohen, K. (2013). Strengthening pharmacovigilance in South Africa. South African Medical Journal, 104 (2), 104.
129. Palleria, C., Leporini, C., Chimirri, S., Marrazzo, G., Sacchetta, S., Bruno, L., et al. (2013). Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports. Journal of Pharmacology & Pharmacotherapeutics, 4 (Suppl 1), S66-S72.
130. Patidar, D., Rajput, M. S., Nirmal, N. P., & Savitri, W. (2013). Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdisciplinary Toxicology, 6 (1), 41-46.
131. Pimpinella, G., & Tartaglia, L. (2013). Pharmacovigilance and the Italian medicines agency. Journal of Pharmacology & Pharmacotherapeutics, 4 (Suppl 1), S4-S6.
132. Saad, A. (2014). Arab pharmacovigilance guidelines (p. 15). UPPSALA Reports. Available from www.who-umc.org
133. Seligman, P. J., & Osborne, S. F. (2009). Perspectives on early communication of drug risks to the public. Clinical Pharmacology and Therapeutics, 85 (3), 335-339.
134. Shin, H. K., Jeong, S. J., Lee, M. S., & Ernst, E. (2013). Adverse events attributed to traditional Korean medical practices: 1999-2010. Bulletin of the World Health Organization, 91 (8), 569-575.
135. Urushihara, H., Kobashi, G., Masuda, H., Taneichi, S., Yamamoto, M., Nakayama, T., et al. (2014). Pharmaceutical company perspectives on current safety risk communications in Japan. Springerplus, 3, 51.
136. Wilbur, K. (2013). Pharmacovigilance in Qatar: A survey of pharmacists. Eastern Mediterranean Health Journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 19 (11), 930-935.
137. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University.
138. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University.
139. Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy, The Welsh School of Pharmacy, Cardiff University.
140. McAuslane, N., Cone, M., Collins, J., & Walker, S. (2009). Emerging markets and emerging agencies: A comparative study of how key regulatory agencies in Asia, Latin America, the Middle East and Africa are developing processes and review models for new medicinal products. Drug Information Journal, 43, 349-359.
141. World Health Organisation (WHO) (2008) WHO Drug Information, 22 (2). Available from: http://apps.who.int/medicinedocs/documents/s14886e/s14886e.pdf.
142. Alder, S. (2001). Methods for setting parameters for submission quality: How do we know if we have got them right? In C. Hynes, N. McAuslane, & S. Walker (Eds.), Building quality measures into the regulatory review process: assessing the needs of industry and regulators (pp. 39-42). Surrey: CMR International.
143. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University.
144. Al-Rubaie, M. (2013). Evaluation of the regulatory review process of the GCC centralised procedure: development of a model for improving the approval process. PhD Thesis, Cardiff University. Doctor of Philosophy thesis.
145. Booz Allen Hamilton Inc. (2008). Independent evaluation of FDA’s first cycle review performance - Final report. Available at: http://www.fda.gov/ForIndustry/UserFees/Prescription DrugUserFee/ucm127117.htm
146. Hill, S., & Johnson, K. (2004). Emerging challenges and opportunities in drug registration and regulation in developing countries. London: DFID Health Systems Resources Centre.
147. Mallia-Milanes, A. (2010). The development and application of scorecards to assess the quality of regulatory submissions and their review. Unpublished Doctor of Philosophy thesis, Welsh School of Pharmacy, Cardiff University, Cardiff.
148. Moore, T. J., & Ferburg, C. D. (2014). Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. JAMA Internal Medicine, 174 (1), 90-95.
149. Anderson, C. (2007). An evaluation of harmonisation in the regulatory environment and its impact on patients’ access to new medicines. Unpublished Doctor of Philosophy, Welsh School of Pharmacy, Cardiff University, UK.
150. CIRS Centre for Innovation in Regulatory Science. (2013). New drug approvals in ICH countries 2003-2012: Focus on 2012. R&D Briefing, 52: 2013.
151. El Boghdady, D. (2012, February 13). FDA budget stays about the same at $2.5 billion. The Washington Post. Retrieved 30 Aug 2012.
152. European Medicines Agency (EMA). (2009). Survey 2008 on the performance of EMEA scientific procedures for medicinal products for human use (EMEA/MB/30754/2009). London: EMA. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500006220.pdf
153. European Medicines Agency (EMA). (2010). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003695.pdf
154. Hashan, H. (2005). Evaluation of the review process for marketing pharmaceutical products in the Gulf States and its impact on patients’ access to medicines. Unpublished Doctor of Philosophy, The Welsh School of Pharmacy, Cardiff University, UK.
155. Heidenreich, K. (2004, October 1). Dialogue between companies and the EMEA regarding the centralized procedure from an industry’s point of view. The first DIA workshop on Regulatory Affairs in Japan, Tokyo.
156. IMS. (2011). The global use of medicines: Outlook through 2015. Report by IMS Institute for Healthcare Informatics. Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Documents/The_Global_Use_of_Medicines_Report.pdf
157. Rahman, L. A. (2002, June 24-27). Centralized drug registration system in the Gulf Region. The tenth international conference of Drug Regulatory Authorities (ICDRA), Hong Kong, p. 166.
158. Ratanawijitrasin, S., & Wondemagegnehu, E. (2002). Effective drug regulation - A multicountry study. [Online] Geneva: WHO. Available from: http://pdfoo.com/ebook-4146/effective-drugregulation.html
159. Therapeutic Goods Administration (TGA). (2009). Guidance for industry on providing regulatory submissions for prescription medicines in electronic format (eCTD) in Australia. Available from: http://www.theectdsummit.com/?m=200901
160. ALPEN Capital Investment Bank. (2010). GCC pharmaceuticals industry. [Online] UAE. Available from: http://www.alpencapital.com/news-article-2-12.htm
161. Darden School of Business Administration. (2009). Strategic thinking. [Online] Available from: http://faculty.darden.virginia.edu/bourgeoisj/files/chapter%205.html
162. Kristofferen, S. (2009). Strategic planning-what-how and when?. [Online] Oct 2009. Available from: http://www.articlesbase.com/print/1301706
163. LeDoux, L., Guilbeau, R., Kirk, S., & Baker, N. (2005). Strategic planning: Managing strategically. Texas Workforce Commission, Training and Development Department. Available from: http://www.twc.state.tx.us/boards/board_plan/strat_planning.pdf
164. McNamara, C. (2006). Overview of basic methods to collect information. Available from: http://www.managementhelp.org/research/overview/htm
165. Mintzberg, H. (1987). The Strategy Concept 1: Five Ps of Strategy. Calif Manage Rev, 30 (1), 25-32.
166. Mintzberg, H., Ahlstrand, B., & Lampel, J. (Eds.). (1998). Strategy safari: A guided tour through the wilds of strategic management. New York: Free Press (Hardcover). ISBN 0-684-84743-4.
167. Pant, P. N., & Lachman, R. (1998). Value incongruity and strategic choice. J Manag Stud, 35, 195-212.
168. Radkte, J. M. (1998). How to write a mission statement. The Grantmanship Center. Available from: https://www.tgci.com/sites/default/files/pdf/How%20to%20Write%20a%20Mission%20Statement.pdf
169. Rekom, J. V., Van Riel, C. B. M., & Wierenga, B. (2006). A methodology for assessing organizational core values. J Manag Stud, 43, 175-210.
170. Seevers, B. S. (2000). Identifying and clarifying organisational values. J Agric Educ, 41 (3), 70-79.
171. Shilder, D. (1997). Strategic planning process: Steps in developing strategic plans. Cambridge, MA: Harvard Family Research Project. Available from: http://www.hfrp.org/publicationsresources/browse-our-publications/strategic-planning-process-steps-in-developingstrategic-plans
172. Yielder, P., & Burns, M. (1999). Effective strategic planning. The Enterprise Foundation. ISBN 0-942901-20-7. Available from: http://www.enterprisefoundation.org
173. Zarkesh, M. (2008). Customizing strategic planning model for Iran’s cement industry. Department of Business Administration and Social Sciences, Lulea University of Technology, Sweden. Master Thesis.
174. Al-Essa, R. (2011). An evaluation of the regulatory review processes, the quality of decisionmaking and strategic planning in the Gulf Cooperation Council (GCC) States. Doctor of Philosophy thesis, The Welsh School of Pharmacy, Cardiff University. Available at: http://orca.cf.ac.uk/54418/1/U584519.pdf.